ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models

CLDN18.2 (Claudin18.2)-targeting therapeutic antibodies have shown promising clinical efficacy in approximately 30% of gastric cancers expressing high levels of CLDN18.2 and less pronounced activity in low expressing malignancies. Here, we report that ZL-1211 is a mAb targeting CLDN18.2 engineered t...

Descripción completa

Detalles Bibliográficos
Autores principales: Konno, Hiroyasu, Lin, Tracey, Wu, Renyi, Dai, Xinchuan, Li, Shou, Wang, Grace, Chen, Min, Li, Wenying, Wang, Lina, Sun, Bee-Chun, Luo, Zhen, Huang, Tom, Chen, Yuping, Zhang, John, Ye, Qiuping, Bellovin, David, Wan, Bing, Kang, Lishan, Szeto, Christopher, Hsu, Karl, Kabbarah, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010325/
https://www.ncbi.nlm.nih.gov/pubmed/36922936
http://dx.doi.org/10.1158/2767-9764.CRC-22-0216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010325/
https://www.ncbi.nlm.nih.gov/pubmed/36922936
http://dx.doi.org/10.1158/2767-9764.CRC-22-0216

Ejemplares similares